Thomas John Dietz net worth and biography

Thomas Dietz Biography and Net Worth

Dr. Dietz is currently chairman and CEO of Waypoint Holdings, LLC, a diversified financial-holdings and services company. He is also the Managing General Partner for Firebrand River Capital, LLC, a biotechnology-focused investment advisory firm founded in 2021. Previously, Dr. Dietz was co-CEO and then CEO and a director of Pacific Growth Equities, LLC, a San Francisco-based investment bank and institutional brokerage firm from 2004 to 2009, when the firm was acquired by Wedbush Securities. Dr. Dietz served as head of the investment banking division at Wedbush until November 2010.

Prior to taking the CEO role at Pacific Growth, Dr. Dietz served as the company's director of equities research and was an award-winning biotechnology and biopharmaceutical analyst. He joined Pacific Growth in 1993. Previously, he was a member of the research faculty in the Department of Medicine, University of California, San Francisco and the VA Medical Center. Dr. Dr. Dietz serves on the boards of several private companies.

Dr. Dietz holds a Ph.D. in molecular biology and biochemistry from Washington University, St. Louis, and was a National Science Foundation Post-Doctoral Fellow.

What is Thomas John Dietz's net worth?: The estimated net worth of Thomas John Dietz is at least $250.43 thousand as of August 26th, 2026. Dr. Dietz owns 132,500 shares of Cypherpunk Technologies stock worth more than $250,425 as of August 28th. This net worth evaluation does not reflect any other investments that Dr. Dietz may own. Learn More about Thomas John Dietz's net worth.
How do I contact Thomas John Dietz?: The corporate mailing address for Dr. Dietz and other Cypherpunk Technologies executives is 47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 USA. Cypherpunk Technologies can also be reached via phone at (617) 714-0360 and via email at [email protected]. Learn More on Thomas John Dietz's contact information.
Has Thomas John Dietz been buying or selling shares of Cypherpunk Technologies?: During the last quarter, Thomas John Dietz has sold $34,400.00 in Cypherpunk Technologies stock. Most recently, Thomas John Dietz sold 20,000 shares of the business's stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $1.72, for a transaction totalling $34,400.00. Following the completion of the sale, the director now directly owns 132,500 shares of the company's stock, valued at $227,900. Learn More on Thomas John Dietz's trading history.
Are insiders buying or selling shares of Cypherpunk Technologies?: During the last twelve months, insiders at the sold shares 1 times. They sold a total of 20,000 shares worth more than $34,400.00. The most recent insider tranaction occured on August, 26th when Director Thomas John Dietz sold 20,000 shares worth more than $34,400.00. Insiders at Cypherpunk Technologies own 3.5% of the company. Learn More about insider trades at Cypherpunk Technologies.
Information on this page was last updated on 8/26/2026.

Thomas John Dietz Insider Trading History at Cypherpunk Technologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/26/2026	Sell	20,000	$1.72	$34,400.00	132,500

Thomas John Dietz Buying and Selling Activity at Cypherpunk Technologies

Cypherpunk Technologies Company Overview

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Today's Range

Now: $1.89

$1.73

$2.05

50 Day Range

MA: $0.79

$0.59

$1.89

2 Week Range

Now: $1.89

$0.27

$3.70

Volume

14,452,713 shs

Average Volume

5,885,929 shs

Market Capitalization

$203.67 million

P/E Ratio

3.38

Dividend Yield

N/A

Beta

0.09